Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes

Diabetic Medicine

Volumn 34, Issue 4, 2017, Pages 531-538

  Park, S K ^a   Harlow, S D ^a   Zheng, H ^a   Karvonen Gutierrez, C ^a   Thurston, R C ^b,c   Ruppert, K ^c   Janssen, I ^d   Randolph, J F ^e  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; GLUCOSE;

ADULT; ARTICLE; BODY MASS; CLIMACTERIUM; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; SELF REPORT; SMOKING; WEIGHT CONTROL; INCIDENCE; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RISK; UNITED STATES;

ADULT; DIABETES MELLITUS, TYPE 2; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MENOPAUSE; MIDDLE AGED; OBESITY; PROPORTIONAL HAZARDS MODELS; RISK; UNITED STATES;

EID: 85008193401     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13301     Document Type: Article

References (30)

1. Jelenik T, Roden M. How estrogens prevent from lipid-induced insulin resistance. Endocrinology 2013; 154: 989–992.
2. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003; 138: 1–9.
3. Perseghin G, Scifo P, Pagliato E, Battezzati A, Benedini S, Soldini L et al. Gender factors affect fatty acids-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. J Clin Endocrinol Metab 2001; 86: 3188–3196.
4. Sites CK, L'Hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005; 90: 2701–2707.
5. Chearskul S, Charoenlarp K, Thongtang V, Nitiyanant W. Study of plasma hormones and lipids in healthy elderly Thais compared to patients with chronic diseases: diabetes mellitus, essential hypertension and coronary heart disease. J Med Assoc Thai 2000; 83: 266–277.
6. Golden SH, Dobs AS, Vaidya D, Szklo M, Gapstur S, Kopp P et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 1289–1295.
7. Phillips GB, Tuck CH, Jing TY, Boden-Albala B, Lin IF, Dahodwala N et al. Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women. Diabetes Care 2000; 23: 74–79.
8. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405–411.
9. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000; 23: 912–918.
10. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007; 50: 2076–2084.
11. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 2009; 94: 4127–4135.
12. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55–60.
13. Mather KM, Kim C, Christophi CA, Aroda VR, Knowler WC, Edelstein SE et al. Steroid sex hormones, sex hormone binding globulin and diabetes incidence in the Diabetes Prevention Program. J Clin Endocrinol Metab 2015; 100: 3778–3786.
14. Randolph JF, Jr, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011; 96: 746–754.
15. Crandall CJ, Tseng CH, Karlamangla AS, Finkelstein JS, Randolph JF, Jr, Thurston RC et al. Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period. J Clin Endocrinol Metab 2013; 98: E654–663.
16. Crawford S, Santoro N, Laughlin GA, Sowers MF, McConnell D, Sutton-Tyrrell K et al. Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition. J Clin Endocrinol Metab 2009; 94: 2945–2951.
17. Sowers MR, Crawford SL, Sternfeld B, Morganstein D, Gold EB, Greendale GA et al. SWAN: A Multicenter, Multiethnic, Community-Based Cohort Study of Women and the Menopausal Transition. In: Lobo RA, J Kelsey, R Marcus, eds. Menopause: Biology and Pathology. San Diego, CA: Academic Press, 2000: 175–188.
18. Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS. Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab 2007; 92: 3060–3067.
19. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159–1168.
20. Sowers MR, Zheng H, McConnell D, Nan B, Harlow S, Randolph JF, Jr. Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endocrinol Metab 2008; 93: 3958–3964.
21. Sowers MR, Zheng H, McConnell D, Nan B, Harlow SD, Randolph JF, Jr. Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab 2008; 93: 3847–3852.
22. De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R. Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity (Silver Spring) 2006; 14: 1954–1960.
23. Freeman EW, Sammel MD, Lin H, Gracia CR. Obesity and reproductive hormone levels in the transition to menopause. Menopause 2010; 17: 718–726.
24. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001; 45: S116–124.
25. Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids 1998; 63: 319–321.
26. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90–119.
27. Sites CK, Calles-Escandon J, Brochu M, Butterfield M, Ashikaga T, Poehlman ET. Relation of regional fat distribution to insulin sensitivity in postmenopausal women. Fertil Steril 2000; 73: 61–65.
28. Wang N, Kuang L, Han B, Li Q, Chen Y, Zhu C et al. Follicle-stimulating hormone associates with prediabetes and diabetes in postmenopausal women. Acta Diabetol 2016; 53: 227–236.
29. Tanko LB, Christiansen C. An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause 2004; 11: 104–109.
30. Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015; 3: 958–967.